

Lianne S Gensler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/629073/publications.pdf>

Version: 2024-02-01

61
papers

3,917
citations

236833

25
h-index

143943

57
g-index

63
all docs

63
docs citations

63
times ranked

4387
citing authors

#	ARTICLE	IF	CITATIONS
1	Virtually Speaking: The Impact of a Nationwide Synchronous and Asynchronous Learning Forum. <i>Arthritis Care and Research</i> , 2023, 75, 1563-1570.	1.5	1
2	Relationship Between Body Mass Index, Disease Activity, and Exercise in Ankylosing Spondylitis. <i>Arthritis Care and Research</i> , 2022, 74, 1287-1293.	1.5	7
3	Identifying trajectories of radiographic spinal disease in ankylosing spondylitis: a 15-year follow-up study of the PSOAS cohort. <i>Rheumatology</i> , 2022, 61, 2079-2087.	0.9	8
4	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 254-261.	3.7	18
5	Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging. <i>Rheumatology</i> , 2022, 61, 4324-4334.	0.9	4
6	Combined Single Cell Transcriptome and Surface Epitope Profiling Identifies Potential Biomarkers of Psoriatic Arthritis and Facilitates Diagnosis via Machine Learning. <i>Frontiers in Immunology</i> , 2022, 13, 835760.	2.2	11
7	Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. <i>RMD Open</i> , 2022, 8, e002138.	1.8	2
8	Reactogenicity of the Messenger <i>RNA SARS-CoV-2</i> Vaccines Associated With Immunogenicity in Patients With Autoimmune and Inflammatory Disease. <i>Arthritis Care and Research</i> , 2022, 74, 1953-1960.	1.5	5
9	Impact of HLA-B27 and Disease Status on the Gut Microbiome of the Offspring of Ankylosing Spondylitis Patients. <i>Children</i> , 2022, 9, 569.	0.6	8
10	Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: 3-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 1943-1958.	2.9	9
11	Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study. <i>Journal of Rheumatology</i> , 2021, 48, 361-366.	1.0	5
12	Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. <i>Journal of Rheumatology</i> , 2021, 48, 188-197.	1.0	7
13	Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies. <i>Rheumatology and Therapy</i> , 2021, 8, 273-288.	1.1	11
14	Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1168-1174.	0.5	49
15	Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1004-1013.	0.5	124
16	Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1022-1030.	0.5	18
17	Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2. <i>Annals of Internal Medicine</i> , 2021, 174, 1572-1585.	2.0	273
18	Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. <i>Arthritis Research and Therapy</i> , 2021, 23, 231.	1.6	17

#	ARTICLE	IF	CITATIONS
19	Do geography and ethnicity play a role in juvenile Spondyloarthritis? A multi-center binational retrospective study. <i>Pediatric Rheumatology</i> , 2021, 19, 4.	0.9	2
20	The Association of Tumor Necrosis Factor Inhibitor Use With Incident Hypertension in Ankylosing Spondylitis: Data From the PSOAS Cohort. <i>Journal of Rheumatology</i> , 2021, , jrheum.210332.	1.0	3
21	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110579.	1.2	30
22	Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 1037.	0.8	8
23	A latent class based imputation method under Bayesian quantile regression framework using asymmetric Laplace distribution for longitudinal medication usage data with intermittent missing values. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 160-177.	0.4	2
24	Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 176-185.	0.5	76
25	Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 920-928.	0.5	53
26	Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis. <i>RMD Open</i> , 2020, 6, e001225.	1.8	20
27	Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2090604.	1.2	34
28	Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort. <i>Rheumatology International</i> , 2020, 40, 1053-1061.	1.5	8
29	The changing profile of ankylosing spondylitis in the biologic era. <i>Clinical Rheumatology</i> , 2020, 39, 2641-2651.	1.0	3
30	Chronic back pain in first-degree relatives (FDRs) of patients with ankylosing spondylitis: predictive value of HLA-B27 and persistence of inflammatory back pain over time. <i>RMD Open</i> , 2020, 6, e001418.	1.8	3
31	Does psoriatic axial spondyloarthritis phenotype correlate with imaging morphotype?. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 329-332.	0.4	3
32	2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1599-1613.	2.9	401
33	MR distribution of active inflammatory and chronic structural sacroiliac joint changes in axial spondyloarthropathy: Challenging conventional wisdom. <i>Clinical Imaging</i> , 2019, 58, 70-73.	0.8	7
34	E098â€fEfficacy and safety outcomes in patients with axial spondyloarthritis treated with certolizumab pegol: results from the 48-week run-in part of a 96-week study (NCT02505542). <i>Rheumatology</i> , 2019, 58, .	0.9	0
35	A Terminal Event. <i>New England Journal of Medicine</i> , 2019, 381, 970-976.	13.9	2
36	A Fiftyâ€Twoâ€Week, Randomized, Placeboâ€Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1101-1111.	2.9	71

#	ARTICLE	IF	CITATIONS
37	Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. <i>Drug Safety</i> , 2019, 42, 751-768.	1.4	93
38	HLA class I and II alleles in susceptibility to ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 66-73.	0.5	52
39	Successful treatment of mucous membrane pemphigoid with bortezomib. <i>JAAD Case Reports</i> , 2018, 4, 81-83.	0.4	10
40	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484
41	Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohort. <i>Journal of Rheumatology</i> , 2018, 45, 188-194.	1.0	20
42	Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 369-389.	1.4	73
43	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet</i> , 2018, 392, 2378-2387.	6.3	198
44	Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1311-1317.	0.5	85
45	Nonradiographic axial spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 816-829.	1.4	19
46	National Lupus Hospitalization Trends Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Pneumonia. <i>PLoS ONE</i> , 2016, 11, e0144918.	1.1	37
47	Physical activity in axial spondyloarthritis—tails from bench to bedside. <i>Clinical Rheumatology</i> , 2016, 35, 1443-1445.	1.0	5
48	American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2016, 68, 151-166.	1.5	53
49	American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 282-298.	2.9	383
50	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. <i>Nature Communications</i> , 2015, 6, 7146.	5.8	220
51	Updates in adult-onset Still disease: Atypical cutaneous manifestations and associations with delayed malignancy. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 294-303.	0.6	43
52	Axial spondyloarthritis: the heart of the matter. <i>Clinical Rheumatology</i> , 2015, 34, 995-998.	1.0	23
53	Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1387-1393.	0.5	69
54	Genetic Dissection of Acute Anterior Uveitis Reveals Similarities and Differences in Associations Observed With Ankylosing Spondylitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 140-151.	2.9	114

#	ARTICLE	IF	CITATIONS
55	Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2014, 28, 807-818.	1.4	22
56	MICA, a gene contributing strong susceptibility to ankylosing spondylitis. Annals of the Rheumatic Diseases, 2014, 73, 1552-1557.	0.5	47
57	The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns. Arthritis and Rheumatology, 2014, 66, 2649-2656.	2.9	81
58	The Impact of Tumor Necrosis Factor $\hat{\pm}$ Inhibitors on Radiographic Progression in Ankylosing Spondylitis. Arthritis and Rheumatism, 2013, 65, 2645-2654.	6.7	391
59	COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis. Rheumatology and Therapy, 0, , .	1.1	1
60	Certolizumab Pegol Efficacy in Patients With $\langle \text{sc} \rangle$ Non $\hat{\text{a}}\text{e}$ Radiographic $\langle \text{sc} \rangle$ Axial Spondyloarthritis Stratified by Baseline $\langle \text{sc} \rangle$ MRI $\langle \text{sc} \rangle$ and $\langle \text{sc} \rangle$ C $\hat{\text{a}}\text{e}$ Reactive $\langle \text{sc} \rangle$ Protein Status: An Analysis From the $\langle \text{sc} \rangle$ C $\hat{\text{a}}\text{e}$ axSpAnd $\langle \text{sc} \rangle$ Study. ACR Open Rheumatology, 0, , .	0.9	0
61	Minimal Impact of the $\langle \text{sc} \rangle$ COVID $\langle \text{sc} \rangle$ $\hat{\text{a}}\text{e}$ 19 Pandemic on Disease Activity and $\langle \text{sc} \rangle$ Health $\hat{\text{a}}\text{e}$ Related $\langle \text{sc} \rangle$ Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b $\langle \text{sc} \rangle$ Open $\hat{\text{a}}\text{e}$ Label $\langle \text{sc} \rangle$ Extension Study. ACR Open Rheumatology, 0, , .	0.9	1